Alkermes plc Stock
Price
Target price
€23.00
€23.00
0.880%
0.2
0.880%
€37.60
06.08.25 / Stuttgart Stock Exchange
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alkermes plc Stock
The Alkermes plc stock is trending slightly upwards today, with an increase of €0.20 (0.880%) compared to yesterday's price.
With 15 Buy predictions and not the single Sell prediction the community is currently very high on Alkermes plc.
With a target price of 37 € there is a hugely positive potential of 60.87% for Alkermes plc compared to the current price of 23.0 €.
Pros and Cons of Alkermes plc in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | 0.880% | -4.959% | -4.167% | -9.449% | -17.857% | -7.593% | 45.570% |
| Icon plc | -6.970% | -16.111% | 5.251% | -52.947% | -35.134% | -42.043% | - |
| Novocure Ltd | -0.890% | 1.496% | -35.311% | -45.124% | -66.456% | -86.857% | -85.307% |
| Ironwood Pharmaceuticals | -0.740% | -4.255% | 7.143% | -88.158% | -83.929% | -94.144% | -92.012% |
Comments
Alkermes plc (NASDAQ: ALKS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes plc (NASDAQ: ALKS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $43.00 price target on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $42.00 price target on the stock, up previously from $33.00.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Q2 Sales Up 14 Percent
Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus
Alkermes Plc EPS Soars Past Forecasts
Alkermes (NASDAQ:ALKS), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported